HeeSeung Lee1,2, Grace Y Wang3, Louise E Curley1,2, John J Sollers4, Rob R Kydd4,5, Ian J Kirk5,2, Bruce R Russell6,7. 1. School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. 2. Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. 3. Department of Psychology, Auckland University of Technology, Auckland, New Zealand. 4. Department of Psychological Medicine, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. 5. Cognitive Neuroscience Research Group, School of Psychology, The University of Auckland, Auckland, New Zealand. 6. School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand. b.russell@auckland.ac.nz. 7. Centre for Brain Research, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. b.russell@auckland.ac.nz.
Abstract
RATIONALE: Piperazine-based designer drugs such as benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 2008 in New Zealand. When administered in combination, BZP + TFMPP have been reported to produce drug-drug synergism in rodents by stimulating the release of dopamine and serotonin. OBJECTIVES: This study was to evaluate the acute event-related potential effects of BZP, TFMPP or the combination of BZP + TFMPP compared with dexamphetamine in young healthy male adults. METHODS: A double-blind, randomised, placebo-controlled study investigated the effects of BZP, TFMPP, the combination of BZP + TFMPP, and dexamphetamine on the event-related potentials during an auditory oddball task. Healthy, right-handed males were given a single oral dose of either BZP (200 mg), TFMPP (60 mg), a combination of BZP + TFMPP (100/30 mg), dexamphetamine (20 mg) or placebo (lactose) and tested both before and 120 min after drug administration. RESULTS: A single dose of either TMFPP (t = -2.29, p = 0.03) or dexamphetamine (t = -2.33, p = 0.02) significantly reduced the P300 amplitude. A similar trend was also found in BZP. In contrast, BZP and TFMPP in combination has no effect. Neither P300 latency nor the mean reaction time was affected by any of the drug treatments. In addition, neither the P100 nor the P200 component was significantly affected following any of the drug treatments. CONCLUSIONS: A single oral dose of BZP or TFMPP, but not the combination of BZP/TFMPP, affected auditory sensory-evoked P300 potential in a manner similar to dexamphetamine.
RCT Entities:
RATIONALE: Piperazine-based designer drugs such as benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been marketed and sold as legal alternatives to dexamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) until 2008 in New Zealand. When administered in combination, BZP + TFMPP have been reported to produce drug-drug synergism in rodents by stimulating the release of dopamine and serotonin. OBJECTIVES: This study was to evaluate the acute event-related potential effects of BZP, TFMPP or the combination of BZP + TFMPP compared with dexamphetamine in young healthy male adults. METHODS: A double-blind, randomised, placebo-controlled study investigated the effects of BZP, TFMPP, the combination of BZP + TFMPP, and dexamphetamine on the event-related potentials during an auditory oddball task. Healthy, right-handed males were given a single oral dose of either BZP (200 mg), TFMPP (60 mg), a combination of BZP + TFMPP (100/30 mg), dexamphetamine (20 mg) or placebo (lactose) and tested both before and 120 min after drug administration. RESULTS: A single dose of either TMFPP (t = -2.29, p = 0.03) or dexamphetamine (t = -2.33, p = 0.02) significantly reduced the P300 amplitude. A similar trend was also found in BZP. In contrast, BZP and TFMPP in combination has no effect. Neither P300 latency nor the mean reaction time was affected by any of the drug treatments. In addition, neither the P100 nor the P200 component was significantly affected following any of the drug treatments. CONCLUSIONS: A single oral dose of BZP or TFMPP, but not the combination of BZP/TFMPP, affected auditory sensory-evoked P300 potential in a manner similar to dexamphetamine.
Entities:
Keywords:
BZP; Combination of BZP and TFMPP; Human ERP; P300; TFMPP
Authors: M Miele; M A Mura; P Enrico; G Esposito; P A Serra; R Migheli; D Zangani; E Miele; M S Desole Journal: Br J Pharmacol Date: 2000-02 Impact factor: 8.739
Authors: A P Anokhin; A B Vedeniapin; E J Sirevaag; L O Bauer; S J O'Connor; S Kuperman; B Porjesz; T Reich; H Begleiter; J Polich; J W Rohrbaugh Journal: Psychopharmacology (Berl) Date: 2000-05 Impact factor: 4.530
Authors: HeeSeung Lee; Grace Y Wang; Louise E Curley; Rob R Kydd; Ian J Kirk; Bruce R Russell Journal: Psychopharmacology (Berl) Date: 2016-06-11 Impact factor: 4.530
Authors: Ana Y Simão; Mónica Antunes; Emanuel Cabral; Patrik Oliveira; Luana M Rosendo; Ana Teresa Brinca; Estefânia Alves; Hernâni Marques; Tiago Rosado; Luís A Passarinha; Maristela Andraus; Mário Barroso; Eugenia Gallardo Journal: Int J Environ Res Public Health Date: 2022-04-17 Impact factor: 4.614